ArticleLeukemia & lymphoma2020

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

Patrick Hagen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.